Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTmeso1: BMS-986504 in MTAP-deficient Relapsed Mesothelioma
NCT07602946Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- May 2026
- Primary completion
- Jul 2027
- Countries
- 1
- Sponsor
- University of Southampton
- Modality
- Small Molecules
- Drugs
- MRTX1719
- Conditions
- mesothelioma
01
Overview
Phase 2, open-label, single-arm trial of MRTX1719 in mesothelioma, sponsored by University of Southampton. Primary endpoints: Molecular profiling of participant's tumour block and Disease Control Rate at 12 weeks. Planned start May 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
BMS-986504
Patients with MTAP-deficient relapsed mesothelioma receiving BMS-986504
03
Who it enrols
Patients with relapsed malignant mesothelioma, MTAP-deficient, who have received at least 1 prior line of systemic therapy, with ECOG 0-1 and adequate organ function.
04
Endpoints
Primary
Molecular profiling of participant's tumour block
Disease Control Rate
Secondary
Further translational research on participant's tumour block
Disease Control Rate
Beyond the preview
Go deeper on NCT07602946.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602946.